Table 4

Willingness to pay and willingness to trade efficacy for osteoporosis medication attributesa
Attributes and levels Willingness to pay Willingness to trade efficacy
(€ per month) (% risk reduction)
Efficacy (1% risk reduction) 3.73 (3.01 to 4.44)
Cost (€1) -2.27 (–1.58 to –2.96)
Drug administration (reference level: weekly oral tablet)
 Monthly oral tablet 16.16 (12.85 to 19.47) -10.16 (–7.88 to –12.50)
 Subcutaneous injection 3-monthly 4.24 (3.72 to 4.76) -2.93 (–2.57 to –3.30)
 Subcutaneous injection 6-monthly 19.53 (17.15 to 21.92) -13.52 (–11.82 to –15.22)
 Intravenous injection 3-monthly -15.28 (–23.23 to –7.34) 8.66 (14.31 to 3.01)
 Intravenous injection yearly 11.75 (5.64 to 17.85) -5.83 (–1.88 to –9.77)
Side-effects (reference level: gastrointestinal disorders)
 Flu-like symptoms 25.21 (13.06 to 20.50) -16.68 (–14.20 to –19.16)
 Skin reactions 16.78 (13.06 to 20.50) -9.48 (–7.13 to –11.83)

Data presented as mean (95% confidence interval). A positive willingness to pay means that patients are willing to pay a personal contribution for the attribute/level, while a negative willingness to trade efficacy means that patients are willing to give up treatment efficacy for the attribute/level. aUsing the conditional constrained distribution.

Hiligsmann et al.

Hiligsmann et al. Arthritis Research & Therapy 2014 16:R36   doi:10.1186/ar4465

Open Data